Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
10/2002
10/03/2002WO2001098355A3 Cgi-69 compositions and methods of use
10/03/2002WO2001096388A3 Compositions and methods for the therapy and diagnosis of colon cancer
10/03/2002WO2001092309A3 Human beta-defensin-3 (hbd-3), a highly cationic beta-defensin antimicrobial peptide
10/03/2002WO2001090150A3 G protein-coupled receptors from human clone '26908' and uses thereof
10/03/2002WO2001083754A3 Cellular regulators of infectious agents and methods of use
10/03/2002WO2001079501A3 Nucleic acid coding for at least one raf partial sequence with a mekk1 binding site
10/03/2002WO2001079465A3 Nucleic acids encoding polypeptides having haloperoxidase activity
10/03/2002WO2001073077A3 Regulation of human serine racemase enzyme
10/03/2002WO2001071004A3 Proteases
10/03/2002WO2001023564A9 Secreted factors
10/03/2002WO2001021812A9 Phosphatases which activate map kinase pathways
10/03/2002WO2001021794A9 Smad associating polypeptides
10/03/2002WO2001019846A9 Transgenically produced fusion proteins
10/03/2002WO2000073502A3 Essential genes and gene products for identifying, developing and optimising immunological and pharmacological active ingredients for the treatment of microbial infections
10/03/2002WO2000069896A9 Molecular interactions in haematopoietic cells
10/03/2002US20020144300 Expression vector coding protein for use in the treatment of diabetes
10/03/2002US20020144298 Novel human genes and gene expression products
10/03/2002US20020143170 Bone morphogenic protein (BMP) polynucleotides, polypeptides, and antibodies
10/03/2002US20020143165 Nucleotide sequences coding polypeptide for use inthe treatment of nervous system disorders and stroke
10/03/2002US20020143159 Bone morphogenetic protein (bmp)-17 and bmp-18 compositions
10/03/2002US20020143156 Nucleotide sequences coding polypeptide for use in the diagnosis and treatment of nervous system, vision, kidney and liver disorders
10/03/2002US20020143155 Nucleotide sequences coding polypeptide for use in the treatment of inflammatory defects
10/03/2002US20020143154 Protein for use in the diagnosis and treatment of tumors
10/03/2002US20020143152 Polypeptide for use in the treatment of hypercholesterolemia, hyperlipemia, diabetes, cancer, pancreatitis, bone, nervvous system, kidney and sexual disorders
10/03/2002US20020143150 Monoclonal antibody to the clonotypic structure of a T-cell receptor, a pharmaceutical composition and a diagnostic reagent comprising the same
10/03/2002US20020143149 Seven trans-membrane receptor-Fitz2
10/03/2002US20020143147 Mammalian genes; related reagents
10/03/2002US20020143142 Genetically engineering transport proteins for use in human and veterninary medicine
10/03/2002US20020143141 Cyclic peptide for use in the treatment of eating disorders
10/03/2002US20020143043 For therapy and prophylaxis of rheumatoid arthritis, or of allergic disorders, asthma, inflammation; inhibitors of the adhesion and migration of leucocytes and/or antagonists of adhesion receptor VLA-4 belonging to the integrins group
10/03/2002US20020143015 Use of vardenafil or pharmaceutically or veterinarily acceptable salt, or solvate in preparation of a medicament for curative, palliative or prophylactic therapy of type 2 diabetes mellitus
10/03/2002US20020142998 For prophylaxis and therapy
10/03/2002US20020142989 Oncolytic/immunogenic complementary-adenoviral vector system
10/03/2002US20020142988 G-coupled receptor showing selective affinity for ATP
10/03/2002US20020142986 Used in the diagnosis or prognosis of liver associated disorders
10/03/2002US20020142984 Administering a positively charged liposome to animal, wherein positively charged liposome is associated with nucleic acid molecule, wherein nucleic acid molecule is in operable association with a promoter
10/03/2002US20020142983 MUC-1 antagonists and methods of treating immune disorders
10/03/2002US20020142982 Method for regulating angiogenesis
10/03/2002US20020142980 Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
10/03/2002US20020142975 Antisense inhibitor of recql4 expression
10/03/2002US20020142968 For therapeutic and/or prophylactic treatment of idiopathic and adult respiratory distress syndrome, pulmonary fibrosis following treatment with radiation or chemotherapy, septic shock, septicemia, inflammatory responses
10/03/2002US20020142967 Thrombin inhibitors
10/03/2002US20020142966 For cancer therapy
10/03/2002US20020142965 Administering to animal peptide wherein the amino acid sequence of peptide comprises the carboxyl-terminal sequence of a growth hormone, and wherein said peptide is not the intact, full-length growth hormone
10/03/2002US20020142964 Single-chain polypeptides
10/03/2002US20020142963 Methods for increasing bone formation and enhancing bone accretion
10/03/2002US20020142962 Inhibition of abnormal cell growth with corticotropin-releasing hormone analogs
10/03/2002US20020142961 As pharmaceuticals, diagnostics, biosensors and bioreactors
10/03/2002US20020142960 Exposing cells to an aggregate formulation which comprises VP22, or a polypeptide with transport function of VP22, and oligonucleotides or polynucleotides; exposing cells to a disaggregating agent which can promote disaggregation
10/03/2002US20020142959 As drugs, diagnostics, biosensors and bioreactors
10/03/2002US20020142958 Secreted and transmembrane polypeptides and nucleic acids encoding the same
10/03/2002US20020142956 Administering an agent which triggers anion efflux in respiratory tissue via the activation of a secretin receptor for therapy of cystic fibrosis
10/03/2002US20020142954 Laminin 15 and uses thereof
10/03/2002US20020142953 Materials and methods relating to lipid metabolism
10/03/2002US20020142950 Methods for enhancing the bioavailability of a drug
10/03/2002US20020142949 Inducing cytotoxicity in a neoplastic cell comprising: contacting said cell with an amount of a GSSP-2 polypeptide
10/03/2002US20020142948 Methods for administration of antibiotics
10/03/2002US20020142947 By muta-synthesis using a mutated micro-organism to influence the biosynthesis of at least one of the precursors of group B streptogramines; mutant strain employed is preferably derived from the strain S. pristinaespiralis SP92
10/03/2002US20020142946 Cyclosporins for the treatment of respiratory diseases
10/03/2002US20020142944 Treatment of ocular disorders
10/03/2002US20020142943 A drug and an agent capable of inducing the dephosphorylation of phosphorylated serine and/or threonine residue of p100 and/or p120, wherein the ability of the drug to cross a physiological barrier is improved.
10/03/2002US20020142939 HMGI proteins in cancer and obesity
10/03/2002US20020142466 Controlling ciliary neurotrophic factor cell signaling; obtain cell, incubate with modulator, monitor cell signaling activity
10/03/2002US20020142464 Nucleotide sequences coding preferential polypeptide for use in the treatment of infections, atherosclerosis, cancer, nervous system, gastrointestinal, muscle, bone, heart, vision, kidney and urogenital disorders
10/03/2002US20020142461 T1 Receptor-like ligand II and uses thereof
10/03/2002US20020142456 Protein for use in the treatment of body weight defects
10/03/2002US20020142448 Antibody for use in the diagnosis, treatment and prevention of bone disorders and cancer
10/03/2002US20020142447 DNA encoding the human serine protease EOS
10/03/2002US20020142446 DNA encoding the human serine protease EOS
10/03/2002US20020142445 Peptides for use in the treatment of tumors and graft versus host disease
10/03/2002US20020142444 AL-2 neurotrophic factor
10/03/2002US20020142442 Tumor suppressor WAF1
10/03/2002US20020142441 Compositions and methods for the treatment and diagnosis of cardiovascular disease
10/03/2002US20020142437 Nucleotide sequences coding enzymatic polypeptide for use in the treatment of respiratory system disorders
10/03/2002US20020142436 Enzymatic protein for use in the treatment of tumors, nervous system, cardiovascular, psychological, pregnancy, bone, kidney, respiratory and alimentary canal disorders
10/03/2002US20020142432 Human endosulfine gene
10/03/2002US20020142430 Peptide for use in the treatment of inflammation, cancer, arteriosclerosis and psoriasis
10/03/2002US20020142429 Elongation factor-2 kinase (EF-2 kinase) and methods of use therefor
10/03/2002US20020142428 Novel kinases and uses thereof
10/03/2002US20020142421 Isolated human aminoacylase, nucleic acid molecules encoding human aminoacylase, and uses thereof
10/03/2002US20020142419 Nucleotide sequences coding polypeptide for use in the diagnosis and treatment of bone disorders and arthritis
10/03/2002US20020142418 Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof
10/03/2002US20020142414 Nucleotide sequences coding polypeptide for use in the treatment of lung defects, septic shock or inflammation
10/03/2002US20020142397 Genetically engineering cell; obtain cell, incubate with cell growth factor, remove nucleus or chromatin, insert into cell, propagate cell
10/03/2002US20020142396 Nucleotide sequences coding polypeptide for use in the treatment of cancer
10/03/2002US20020142395 Proteins for use in the treatment of tumor, arthritis and vision defects
10/03/2002US20020142392 Human melanocyte stimulating hormone receptor polypeptide and DNA
10/03/2002US20020142391 Synthesis of human procollagens and collagens in recombinant DNA systems
10/03/2002US20020142389 Soluble T cell receptor
10/03/2002US20020142383 Isolated nucleic acid molecules encoding human transport proteins
10/03/2002US20020142382 Isolated human Ras-like proteins, nucleic acid molecules encoding these human Ras-like proteins, and uses thereof
10/03/2002US20020142377 18607, a novel human calcium channel
10/03/2002US20020142373 Tissue factor protein variants
10/03/2002US20020142372 Fragments of cr1 and their use
10/03/2002US20020142363 Medical diagnosis, therapy; detecting binding of proteins
10/03/2002US20020142359 Monoclonal antibody to CEA, conjugates comprising said antibody, and their therapeutic use in an adept system
10/03/2002US20020142357 TNF receptor action modulation
10/03/2002US20020142353 Connective tissue growth factor (CTGF) and methods of use
10/03/2002US20020142346 Binding compounds and methods for identifying binding compounds
10/03/2002US20020142330 Novel glutamate receptor modulatory proteins and nucleic acid molecules and uses therefor
1 ... 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 ... 3163